Intralesional immunotherapy of brain tumors with combined Corynebacterium parvum and recombinant interleukin-2 in mice.
Clinical observations and experimental work suggested that inflammatory cells attracted to the brain exert a nonspecific antineoplastic effect. Intralesional treatment of implanted malignant murine brain tumors (KHT sarcomas) with killed Corynebacterium parvum produced an inflammatory cell infiltrate and increased survival in C3H mice relative to that in untreated control C3H mice. This antitumor effect was enhanced when recombinant interleukin-2 was sequentially added as a second intralesional immunomodifier. A high percentage of mice so treated were cured. Inflammatory cells in the brains of treated mice divided for 1-2 weeks, and metabolic activity of astrocytes increased. These findings form the basis for a recently initiated immunotherapy protocol in patients with recurrent glioblastoma multiforme.
Conley
F K
FK
Division of Neurosurgery, Stanford University School of Medicine, CA 94305.
Adler
J R
JR
Duncan
J A
JA
Kennedy
J D
JD
Sutton
R C
RC
D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000628:therapy*; D003352:Corynebacterium / Q000276:immunology*; D005260:Female; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology; D015552:Injections, Intralesional; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D012513:Sarcoma, Experimental / Q000628:therapy*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D001428:Bacterial Vaccines; D007376:Interleukin-2; D011994:Recombinant Proteins; D015164:Vaccines, Inactivated